泰恩康：全资子公司收到硫酸氨基葡萄糖胶囊药品注册受理通知书

Core Viewpoint - The company announced that its wholly-owned subsidiary has received a drug registration acceptance notice for glucosamine sulfate capsules from the National Medical Products Administration of China [1] Company Summary - The drug is indicated for primary and secondary osteoarthritis and was first approved in Italy in 1982 and in China in 1996 [1] - The sales amount for the drug in domestic urban and county public hospitals, urban and online pharmacies, urban community hospitals, and township health centers is projected to be approximately 3.362 billion RMB in 2024 [1] - Currently, there are 13 companies in China that have obtained drug registration certificates for this product [1]